Template:Tamoxifen dosage and incidence of breast symptoms with bicalutamide in men
| Follow-up timepoint |
Tamoxifen dosage | |||||
|---|---|---|---|---|---|---|
| Placebo | 1 mg/day | 2.5 mg/day | 5 mg/day | 10 mg/day | 20 mg/day | |
| 0 months | –
| |||||
| 6 months | 98% | 90% | 80% | 54% | 22% | 10% |
| 12 months | 99% | 95% | 84% | 56% | 38% | 19% |
| Notes: Prevention of breast symptoms—specifically gynecomastia and breast pain—induced by 150 mg/day bicalutamide monotherapy with tamoxifen in 282 men with prostate cancer. Bicalutamide and tamoxifen were initiated at the same time (0 months). Estradiol levels were in the range of about 22 to 47 pg/mL in the treated group.[1] Sources: [2][1] | ||||||
Template documentationReferences
- ^ a b Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, Morris T, Navani S (July 2007). "Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study". Eur. Urol. 52 (1): 106–14. doi:10.1016/j.eururo.2007.01.031. PMID 17270340.
- ^ Fentiman IS (January 2018). "Managing Male Mammary Maladies". Eur J Breast Health. 14 (1): 5–9. doi:10.5152/ejbh.2017.3841. PMC 5758064. PMID 29322112.